Outlook Therapeutics submits HCPCS application for LYTENAVA
Outlook Therapeutics said it submitted a HCPCS Level II application to CMS for a permanent J-Code for LYTENAVA (bevacizumab-vikg).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.